吸入噻托溴铵联合舒利迭治疗稳定期中重度COPD的临床研究

Clinical observation of stable moderate and severe COPD on the treatment of tiotropium bromide inhalation combined seretide for patients

目的研究吸入噻托溴铵联合舒利迭治疗稳定期中重度慢性阻塞性肺疾病(COPD)的治疗效果。方法 45例稳定期中重度COPD患者(完成实验43例,因病情加重退出实验2例)随机分成两组,治疗组给予噻托溴铵(商品名:思力华)及舒利迭(沙美特罗/氟替卡松)吸入治疗12周,对照组给予舒利迭吸入治疗12周,比较两组治疗前后临床症状、体征、血氧饱和度及肺功能主要指标。结果与对照组比较,治疗组FEV1/FVC以及FEV1占预计值百分比显著提高,临床症状体征及血氧饱和度明显改善(P<0.05)。结论吸入噻托溴铵联合舒利迭可有效改善肺功能并缓解临床症状。

Objective To observe the therapeutic effect of inhaled tiotropium combined seretide in patients with stable moderate to severe chronic obstructive pulmonary disease（COPD）.Methods 45 patients with stable moderate to severe COPD patients（completion of the pilot,43 cases out of experiment 2 because of sicker patients）were randomly divided into two groups：treatment group given tiotropium bromide（trade name：spiriva）and seretide（salmeterol,special Luo / fluticasone）inhalation for 12 weeks,control group was given 12 weeks of inhalation treatment seretide,and clinical symptoms,signs,oxygen saturation and pulmonary function key indicators were compared between the two groups before and after the treatment.Results Compared with the control group,FEV1/FVC and FEV1 of the treatment group accounting for percentage of predicted value significantly improved,and the clinical symptoms and signs and blood oxygen saturation improved significantly（P〈0.05）.Conclusion Tiotropium bromide inhalation combined seretide is effective in improving lung function and can alleviate the clinical symptoms.